Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 29

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 29
---
 5% of any class of our voting securities, an officer with knowledge of the proposed transaction, must present information regarding the proposed related person transaction to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board) for review. To identify related person transactions in advance, we rely on information supplied by our executive officers, directors, and certain significant stockholders. In considering related person transactions, our Audit Committee considers the relevant available facts and circumstances, which may include, but not limited to:

the risks, costs, and benefits to us;

the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;

the terms of the transaction;

the availability of other sources for comparable services or products; and

the terms available to or from, as the case may be, unrelated third parties.

Our Audit Committee will approve only those transactions that it determines are fair to us and in our best interests. All of the transactions described above were entered into prior to the adoption of such policy.

The following includes a summary of any related party transactions during the last two completed fiscal years to which we have been a party. We also describe below certain other transactions with our directors, executive officers and 5% stockholders. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties.

May 2024 PIPE Financing

In May 2024, we entered into a purchase agreement whereby we issued and sold in a private placement (the “May 2024 PIPE Financing”): (i)3,591,532 shares of common stock (“Private Placement Shares”), or, at the election of each purchaser, prefunded warrants. Each Private Placement Share or prefunded warrant was accompanied by (i) one May 2024 Series A Warrant, for an aggregate of 3,591,532May 2024 Series A Warrants, and (ii) oneMay 2024 Series B Warrant, for an aggregate of 3,591,532May 2024 Series B Warrants, for aggregate gross proceeds ofapproximately$19.25 million. Among the purchasers were certain of our directors and officers.

PIPE Financing Registration Rights

In connection with the May 2024 PIPE Financing, in May 2024 we entered into a